Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
Rhea-AI Summary
Zenas BioPharma (Nasdaq: ZBIO) announced that management will present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit. The on-demand presentation will be available starting Monday, June 15, 2026, at 7:00 a.m. ET.
Investors can access the webcast and archived replay under “Events and Presentations” in the Investor & Media Relations section of the company’s website.
Positive
- None.
Negative
- None.
News Market Reaction – ZBIO
In the Jun 12 session, ZBIO gained 11.49%, reflecting a significant positive market reaction. Argus tracked a peak move of +18.2% during that session. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 02 | Phase 3 data update | Positive | +1.6% | INDIGO Phase 3 obexelimab data and BLA submission details released. |
| May 28 | BLA submission | Positive | +2.6% | BLA filed with FDA for obexelimab in IgG4-RD supported by Phase 3 results. |
| May 19 | Trial results preview | Positive | +6.5% | Announcement of upcoming EULAR 2026 presentation of INDIGO Phase 3 data. |
| May 18 | Equity compensation grants | Neutral | +6.5% | Inducement RSU grants to new employees under Nasdaq Listing Rule 5635(c)(4). |
| May 13 | Phase 1 trial start | Positive | +4.0% | First subject dosed in Phase 1 trial of oral IL-17 inhibitor ZB021. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, especially clinical and regulatory milestones, has generally been followed by modestly positive price reactions.
Over the past month, ZBIO has issued a series of clinically focused updates and corporate actions. Phase 3 INDIGO data for obexelimab in IgG4-RD met primary and key secondary endpoints, with a BLA submitted to the FDA and data highlighted at EULAR 2026 and in the New England Journal of Medicine. The company also advanced ZB021 into Phase 1 and granted 51,075 RSUs to new employees. These announcements saw generally positive 24-hour price reactions, framing today’s conference participation against a backdrop of recent fundamental progress.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced management’s presentation at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit. The presentation will be available on-demand beginning on Monday, June 15, 2026, at 7:00 a.m. ET.
A webcast and archived replay of the Company’s presentation can be accessed under “Events and Presentations” in the Investor & Media Relations section of the Zenas BioPharma website.
About Zenas BioPharma, Inc.
Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases. Zenas’ core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. Zenas believes that the unique mechanism of action of obexelimab and its self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib’s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas’ earlier stage programs include ZB021, a novel, potentially best-in-class, oral small molecule IL-17AA/AF inhibitor, ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor, and ZB014, a preclinical, half-life extended anti-CD19 and FcγRIIb monoclonal antibody. For more information about Zenas BioPharma, please visit https://zenasbio.com/ and follow us on LinkedIn.
The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies.
Investor and Media Contact:
Argot Partners
Zenas@argotpartners.com
